Abstract Number: 038 • 2020 Pediatric Rheumatology Symposium
Change in Treatments and Outcomes After Implementation of a National Diagnosis and Treatment Guarantee Program for Juvenile Idiopathic Arthritis in Chile
Background/Purpose: Juvenile idiopathic arthritis (JIA) is currently the most common childhood chronic rheumatic disease with high burden and socioeconomic costs for the patient’s family and…Abstract Number: 060 • 2020 Pediatric Rheumatology Symposium
Parsing Apart the Pain Experience: Exploring Treatment-Related Pain in Juvenile Idiopathic Arthritis
Background/Purpose: Pain is one of the most frequently reported symptoms among children with Juvenile Idiopathic Arthritis (JIA), and in recent decades our understanding and assessment…Abstract Number: 065 • 2020 Pediatric Rheumatology Symposium
Prosthetic Temporomandibular Joint Replacement in a Cohort of Adolescent Patients with Juvenile Idiopathic Arthritis
Background/Purpose: Temporomandibular joint (TMJ) arthritis is present in 40-96% of children with Juvenile Idiopathic Arthritis (JIA) (1). TMJ arthritis can be difficult to identify, treat,…Abstract Number: 067 • 2020 Pediatric Rheumatology Symposium
Response to Treatment with Intra-articular Triamcinolone Hexacetonide and Triamcinolone Acetonide in Oligo-articular Juvenile Idiopathic Arthritis
Background/Purpose: Oligo-articular juvenile idiopathic arthritis (Oligo JIA) is the most common subtype of juvenile idiopathic arthritis. Intra-articular corticosteroid (IAC) injection is a mainstay treatment of…Abstract Number: 080 • 2020 Pediatric Rheumatology Symposium
Therapeutic Interferon Gamma Neutralization with Emapalumab in Patients with NRLC4- and CDC42-Associated Diseases Characterized by Recurrent and Severe Hemophagocytic Lymphohistiocytosis
Background/Purpose: Interferon gamma (IFNγ) is a pivotal mediator of HLH. Emapalumab (a fully human anti-IFNγ monoclonal antibody) is efficacious in patients with primary HLH. In…Abstract Number: 093 • 2020 Pediatric Rheumatology Symposium
Treatment of Systemic Juvenile Idiopathic Arthritis in the CARRA Registry
Background/Purpose: The treatment of systemic juvenile idiopathic arthritis (SJIA) has changed dramatically over the past decade, associated with overall improvement in functional outcomes. There may…Abstract Number: 098 • 2020 Pediatric Rheumatology Symposium
Early Treatment with Anakinra in Systemic Juvenile Idiopathic Arthritis
Background/Purpose: Systemic juvenile idiopathic arthritis (sJIA) should be considered as a polygenic autoinflammatory disease. Interleukin 1 (IL-1) has been shown to be a major mediator…Abstract Number: L11 • 2019 ACR/ARP Annual Meeting
Maintenance of Remission Following Dose De-Escalation of Abatacept in Early, MTX-Naïve, ACPA-Positive Patients with RA: Results from a Randomized Phase IIIb Study
Background/Purpose: Although EULAR/ACR guidelines suggest tapering biologics following sustained remission in patients (pts) with RA, specific de-escalation (DE) regimens are not fully defined. The Phase…Abstract Number: L13 • 2019 ACR/ARP Annual Meeting
Guselkumab, an Anti-interleukin-23p19 Monoclonal Antibody, in Biologic-naïve Patients with Active Psoriatic Arthritis: Week 24 Results of the Phase 3, Randomized, Double-blind, Placebo-controlled Study
Background/Purpose: Guselkumab (GUS), an anti-interleukin-23p19 monoclonal antibody, is approved for psoriasis (PsO). We assessed GUS efficacy and safety in DISCOVER-1 (ACR2019 Abstract ID697955) and DISCOVER-2,…Abstract Number: L17 • 2019 ACR/ARP Annual Meeting
Efficacy and Safety of Anifrolumab in Patients with Moderate to Severe Systemic Lupus Erythematosus: Results of the Second Phase 3 Randomized Controlled Trial
Background/Purpose: Anifrolumab, a human monoclonal antibody to the type I IFN receptor subunit 1, had robust efficacy in a phase 2 study in patients with…Abstract Number: 504 • 2019 ACR/ARP Annual Meeting
A Subgroup Analysis of the Efficacy of Filgotinib in Demographic and Clinical Subgroups of Patients with Refractory Rheumatoid Arthritis
Background/Purpose: RA patients who have failed biologic DMARDs represent an unmet medical need. We explored the impact of baseline demographics and clinical characteristics on filgotinib…Abstract Number: 614 • 2019 ACR/ARP Annual Meeting
Tapering of Tumor Necrosis Factor Inhibitor and Healthcare Cost Differences in Patients with Ankylosing Spondylitis: A Retrospective Analysis of Korean National Health Insurance Data
Background/Purpose: Tapering of tumor necrosis factor (TNF) inhibitors may be considered in patients with ankylosing spondylitis (AS) with low disease activity. However, there is still…Abstract Number: 1404 • 2019 ACR/ARP Annual Meeting
Treatments Patterns Among Patients with Rheumatoid Arthritis Treated with a Biologic Disease-modifying Anti-rheumatic Drug: A Nation-wide Study in Korea
Background/Purpose: Limited data are available on whether patients with rheumatoid arthritis (RA) are treated with conventional disease-modifying anti-rheumatic drugs (cDMARDs) according to the current recommendations…Abstract Number: 2361 • 2019 ACR/ARP Annual Meeting
Early Treatment of Rheumatoid Arthritis with Disease-Modifying Anti-Rheumatic Drugs at < 3 versus 3-6 Months from Onset of Symptoms: Results from a Cohort of Hispanics from Puerto Rico
Background/Purpose: There is no doubt that early treatment of rheumatoid arthritis (RA) with disease-modifying anti-rheumatic drugs (DMARDs) is associated with better long-term outcomes. However, the…Abstract Number: 507 • 2019 ACR/ARP Annual Meeting
Inhibition of Joint Destruction in Patients with Rheumatoid Arthritis Treated with Peficitinib in Combination with Methotrexate: A Randomized, Double-Blind, Placebo-Controlled Trial in Japan
Background/Purpose: Peficitinib (PEF), a novel oral Janus kinase (JAK) inhibitor, has demonstrated efficacy in Phase 3 studies of patients with RA (NCT02305849).1 We report the…
- « Previous Page
- 1
- 2
- 3
- 4
- …
- 22
- Next Page »